Honeywell Shares Rise After Quantinuum IPO Sets $12.7 Billion Bar for HON
Honeywell rose 0.9% to $233.86 after its quantum unit Quantinuum set terms for a Nasdaq IPO
CRMT Stock Drops Again as America’s Car-Mart Faces Financing Pressure
America’s Car-Mart stock opened at $11.77 Wednesday, near its 52-week low, after closing at $11.73 Tuesday. The company plans to close 42 of its 136 dealerships and cut staff, following a 22%
Terra Innovatum Faces Nasdaq Warning as NKLR Slides
Terra Innovatum closed Nasdaq trading Tuesday at $6.25, down 20 cents, after a compliance notice over late SEC filings. The company must file overdue reports or submit a plan by June 15. Shares fell despite gains in other nuclear stocks, with Oklo, NuScale Power, and Nano Nuclear Energy all trading higher. Terra’s CFO said the delays stem from technical accounting issues, not financial performance.
United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone
United Therapeutics shares rose 1.4% to $576.30 Tuesday after reporting Phase 3 trial data showing Tyvaso improved lung function and reduced risk of worsening in idiopathic pulmonary fibrosis. The company plans to file for FDA approval by summer’s end. Revenue fell 2% last quarter to $781.5 million, with Tyvaso sales slipping. Liquidia’s rival drug Yutrepia posted $130 million in Q1 sales after last year’s FDA nod.
CEPT Stock Sits Quiet, But Cantor Equity Partners II Keeps Some Attention
Cantor Equity Partners II Inc. fell 2 cents to $12.95 Tuesday as traders watched its planned merger with Securitize. About 433,600 shares traded in a $12.75–$13.05 range, putting market cap near $396 million. CEPT’s price stayed above its $10 IPO level, reflecting interest in the Securitize deal. The merger still faces shareholder approval and regulatory hurdles.
BridgeBio shares slip as 2031 drug pricing risk pops up
BridgeBio Pharma shares fell 2.8% to $67.18 after Raymond James downgraded the stock, citing payer-driven risks for its heart drug Attruby. The downgrade follows concerns that insurers may favor cheaper generics as Pfizer’s Vyndamax nears loss of exclusivity in 2031. BridgeBio reported $194.5 million in Q1 revenue, mostly from Attruby, and approved a $500 million buyback. The stock lagged biotech sector gains Tuesday.
Intuit Drops Again With TurboTax AI Questions Back in Focus
Intuit shares fell 3.8% to $307.93 midday Tuesday, underperforming tech peers after Mizuho cut its price target to $500 from $600. The drop followed weak TurboTax results, rising AI competition, and news of a 17% staff cut. Intuit raised its full-year revenue forecast but lowered its TurboTax outlook. The company expects up to $340 million in restructuring charges.
Baozun Shares Rise After Holiday Reopening With Turnaround Still in Focus
Baozun Inc. ADSs rose 2.8% to $2.57 in early Nasdaq trading Tuesday, outpacing larger China internet stocks after reopening from the Memorial Day holiday. The move followed last week’s earnings, where Baozun posted a first-quarter swing to a slim non-GAAP operating profit and 15.3% revenue growth. Operating margin was 0.01%, with a net loss to ordinary shareholders. Director Bin Yu received 24,000 RSUs on May 21.
Akamai Stock Heads Into New Test After $3.5 Billion AI Cloud Move
Akamai traded at $147.23 before the Nasdaq opened Tuesday, following its $3.5 billion zero-coupon convertible note sale to fund cloud infrastructure. The company used $236.6 million for note hedges and spent about $350 million repurchasing shares. Akamai’s CIS revenue rose 40% to $95 million last quarter. Shares are down 2.3% from May 18 highs.
TransMedics Stock Has a Post-Holiday Test — The Next Catalyst Is Already on the Calendar
TransMedics Group shares traded at $68.94 in premarket Tuesday, up 0.2% after the Memorial Day break, valuing the company near $2.5 billion. The move followed a May earnings report showing 21% revenue growth but a sharp drop in net income to $7.3 million. No new company news was posted after May 21. Wall Street analysts cut price targets earlier in May but mostly kept positive ratings.
Baozun Shares Rise After Holiday Reopening With Turnaround Still in Focus
Baozun Inc. ADSs rose 2.8% to $2.57 in early Nasdaq trading Tuesday, outpacing larger China internet stocks after reopening from the Memorial Day holiday. The move followed last week’s earnings, where Baozun posted a first-quarter swing to a slim non-GAAP operating profit and 15.3% revenue growth. Operating margin was 0.01%, with a net loss to ordinary shareholders. Director Bin Yu received 24,000 RSUs on May 21.
Akamai Stock Heads Into New Test After $3.5 Billion AI Cloud Move
Akamai traded at $147.23 before the Nasdaq opened Tuesday, following its $3.5 billion zero-coupon convertible note sale to fund cloud infrastructure. The company used $236.6 million for note hedges and spent about $350 million repurchasing shares. Akamai’s CIS revenue rose 40% to $95 million last quarter. Shares are down 2.3% from May 18 highs.
TransMedics Stock Has a Post-Holiday Test — The Next Catalyst Is Already on the Calendar
TransMedics Group shares traded at $68.94 in premarket Tuesday, up 0.2% after the Memorial Day break, valuing the company near $2.5 billion. The move followed a May earnings report showing 21% revenue growth but a sharp drop in net income to $7.3 million. No new company news was posted after May 21. Wall Street analysts cut price targets earlier in May but mostly kept positive ratings.
Gilead Stock Gets FDA Nod, But Investors Face Hurdle
Gilead Sciences closed at $134.36, up 2.96%, ahead of Memorial Day after the FDA cleared Hepcludex as the first U.S. treatment for chronic hepatitis delta virus. The drug won accelerated approval, with confirmatory data still pending and a boxed warning for severe relapses. U.S. markets reopen Tuesday, when Gilead will see its first trading session post-approval.
ZoomInfo Stock’s Brutal Reset Sets Up a Post-Holiday Test for Wall Street
ZoomInfo shares closed Friday at $3.61, near a one-year low, after a week of selling and a recent guidance cut. The company reported Q1 revenue of $310.2 million, up 1.5%, but lowered its full-year outlook and announced a restructuring affecting about 600 employees. Analysts at Jefferies and Piper Sandler downgraded the stock, citing weak demand and client churn.
Ambarella Up 8% This Week With AI Earnings On Deck
Ambarella shares rose 4.67% Friday to $87.55 ahead of fiscal Q1 results due after the bell Thursday. The stock gained 7.9% last week, outperforming the Philadelphia Semiconductor Index. Nasdaq will close Monday for Memorial Day, with regular trading resuming Tuesday. Analysts maintain a Buy consensus, but Ambarella’s heavy reliance on WT Microelectronics and competition from Mobileye and Nvidia remain risks.
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech
Phio Pharmaceuticals shares rose 1.39% to $1.095 Wednesday as the company prepared to present its PH-762 skin-cancer program at a virtual investor event. CEO Robert Bitterman will discuss the INTASYL platform and Phase 1b results, which showed a 65% response rate among cutaneous squamous cell carcinoma patients. Phio plans to seek FDA feedback on its next trial design in Q2 2026. Market cap stood near $12.55 million.
Traders Eye $850 Million ThomasLloyd Deal as Roman DBDR Stock Stays Quiet
Roman DBDR Acquisition Corp. II closed at $10.52 Wednesday, just below its $10.56 redemption value, with about 115,000 shares traded. The stock’s movement remains tied to its pending merger with ThomasLloyd Climate Solutions, valued at $850 million. Roman reported a Q1 net loss of $235,067 and $242.8 million in its trust account as of March 31. Management cited “substantial doubt” about ongoing operations.
Northeast Community Bancorp Gains After Shareholders Approve 2026 Equity Plan
NorthEast Community Bancorp shares rose 0.6% to $24.39 in midday trading Wednesday after shareholders approved the 2026 equity incentive plan and elected four directors, according to an SEC filing. The vote came a day after the company’s annual meeting and two days after the Memorial Day market holiday. Trading volume reached 8,764 shares. The stock traded between its 52-week high of $25.61 and low of $19.27.
Quantum X Labs Shares Edge Up After New CliniQuantum Info as Markets Wait on Cash Update
Quantum X Labs shares rose 2.7% to $4.26 Wednesday after NeuroThera disclosed new details on a CliniQuantum license deal involving Quantum X’s technology. The company named Technion professor Oren Kurland to its new scientific advisory board. Quantum X remains early-stage and flagged a going-concern risk in filings. Trading volume stayed thin at 27,676 shares.
Why Omeros Stock Is Sliding Today Even as Biotech Shares Climb
Omeros shares fell 3.9% to $11.20 in late-morning trading Wednesday, underperforming biotech sector ETFs, which gained. The drop followed the company’s first U.S. launch of YARTEMLEA, which posted $9.9 million in Q1 sales after FDA approval in December. Investors are watching for upcoming reimbursement milestones and a pending European review.
Accuray Stock Nearly Hit 50 Cents — Then the Rally Faded
Accuray Inc. shares fell 0.9% to $0.3712 by late morning in New York after an early surge to $0.4982, with over 14.4 million shares traded. The drop followed the company’s withdrawal of 2026 guidance, citing Middle East shipment delays and a 7% revenue decline last quarter. Analyst downgrades and a May 22 SEC filing showing TCW’s 13.7% stake added pressure. No new corporate news was released Wednesday.
Golar LNG slides even after posting record quarterly results
Golar LNG shares fell 2.6% to $50.47 by midday Wednesday, underperforming peers after last week’s earnings. Investors weighed a strategic review and plans for a fourth floating LNG unit as energy stocks broadly declined. Golar reported first-quarter revenue up 120% to $137.6 million and will pay a 25-cent dividend June 10. Goldman Sachs is advising on strategic options, but no timeline or outcome is set.
Unity Bancorp Gains as Dividend Date Approaches
Unity Bancorp shares edged up 0.2% to $55.77 Wednesday, bucking declines among regional banks as its June 4 dividend record date neared. The bank reported first-quarter net income of $14.3 million, down from $15.5 million in the prior quarter. Nonaccrual assets rose to $32.1 million, with nearly half tied to one commercial real estate loan. Trading volume reached 14,313 shares.
CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test
CapsoVision shares rose 0.8% to $6.67 in late morning trading Wednesday, bucking a 1.4% drop in the medical-device sector. No new company news was released; investors focused on pending FDA clearance for its AI-assisted reading tool and a planned third-quarter colon-capsule filing. First-quarter revenue held steady at $2.8 million, while gross margin slipped to 48% amid higher costs.
Julong falls after Nasdaq trading pause for JLHL
Julong Holding shares fell 9.1% to $17.44 Wednesday after a Nasdaq volatility halt late Tuesday. The stock hit a low of $16.11 and traded lightly, with about 19,344 shares changing hands. No new statements appeared from the company, whose last investor update was a February annual report filing. Julong reported fiscal 2025 revenue of 252 million yuan and net income of 26.2 million yuan.
Worksport Stock Gets Patent News — Why WKSP Is Still Fighting for Lift
Worksport Ltd. shares rose about 1% Wednesday after its Terravis Energy unit received a U.S. patent for a heat-pump system designed to reduce frost buildup. The move follows a 15.7% drop in the stock Tuesday. First-quarter net sales climbed 47.9% to $3.31 million, but cash reserves fell to $566,000. Management does not expect revenue from the new technology in 2026.
BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle
BioNexus Gene Lab Corp. rose 1.45% to $2.10 in light Nasdaq trading Wednesday, with under 3,000 shares changing hands. First-quarter revenue dropped to $22,842 from $2.14 million a year ago, mainly due to weaker Chemrex results. The company is seeking to recover $2.94 million from former Chemrex officers over disputed payments. BioNexus warned of “substantial doubt” about its ability to continue as a going concern.
Alector Shares Up, Focus Turns to Pipeline After Setback
Alector shares rose 3.7% to $2.27 late Wednesday morning on the Nasdaq, outperforming a 1.2% gain in the XBI biotech ETF. The move follows last month’s halt of its GSK-partnered Alzheimer’s trial for futility and comes as investors weigh its early-stage brain-delivery platform against ongoing cash burn and a new $125 million stock sale program.
Honeywell Shares Rise After Quantinuum IPO Sets $12.7 Billion Bar for HON
Honeywell rose 0.9% to $233.86 after its quantum unit Quantinuum set terms for a Nasdaq IPO targeting a $12.7 billion valuation. Quantinuum plans to offer 21.05 million shares at $45–$50 each, expecting net proceeds of about $941.7 million. Honeywell will retain about 49.1% voting power post-offering. Barclays raised its Honeywell price target to $251, maintaining an overweight rating.
Goldman issues warning on CooperCompanies ahead of earnings
CooperCompanies shares rose 0.4% to $62.28 after Goldman Sachs cut its price target to $61 and reiterated a Sell rating. The company’s fiscal Q2 results are due June 4. Cooper posted Q1 revenue of $1.024 billion, up 6%, and set a 2026 adjusted EPS outlook of $4.58 to $4.66. $1.5 billion remains on its 2021 term loan, with a recent U.K. tax ruling noted in its latest 10-Q.
E.W. Scripps Stock Pauses as SSP Battle Stays Active
E.W. Scripps shares rose 0.6% to $3.44 early Wednesday, outpacing the SPDR S&P 500 ETF, which slipped 0.1%. The company reported $517 million in first-quarter revenue and an $18 million loss, with $2.55 billion in long-term debt as of March 31. Scripps rejected Sinclair’s $622 million bid in December; the stock now trades at less than half that offer.
Comscore Shares Dip Ahead of Friday Update
Comscore shares fell 1.7% to $6.57 in early Nasdaq trading Wednesday after a 4.2% gain Tuesday. First-quarter revenue slipped 0.5% to $85.3 million, with cross-platform revenue up 30.4% but syndicated audience revenue down 4.7%. Net loss widened to $6.2 million. Investors await a strategy update by May 29 as the company faces stiff competition and tight liquidity.
Talphera Trades Around 80 Cents With Focus on Single Trial Catalyst
Roundhill Memory ETF (DRAM) reached $10 billion in assets in 50 days, breaking the record for fastest ETF to that mark. The fund surged 87% since its April 2 launch as Micron, Samsung, and SK Hynix rallied on AI-driven memory-chip demand. Filings show Wall Street preparing a 2x leveraged version. Micron and SK Hynix both briefly topped $1 trillion in value this week.
Bassett Furniture Stock Slips Before the Open — Dividend Date and Housing Worries Put BSET in Focus
Bassett Furniture shares fell 1.2% to $14.46 ahead of Wednesday’s session, valuing the company at about $125 million. The stock is two days from a 20-cent quarterly dividend payment. First-quarter net sales dropped 2.2% to $80.3 million, with operating income at $1.2 million. CEO Rob Spilman cited weak housing demand and severe weather for the slowdown.
First Interstate BancSystem Stock Is Back in Focus After Shelf Filing and Analyst Cut
First Interstate BancSystem filed an automatic shelf registration Tuesday, allowing it to sell various securities in the future. Shares closed up 1.8% at $36.13 after D.A. Davidson downgraded the stock to Neutral and cut its price target. The filing comes ahead of Wednesday’s shareholder meeting in Billings, Montana. First-quarter net income rose to $60.2 million from $50.2 million a year earlier.